Myokardia develops therapies and treatments for inherited heart conditions, particularly hypertrophic cardiomyopathy or HCM, which affects 650,000 people in the U.S. Myokardia CEO Tassos Gianakakos joins ‘Closing Bell’ to discuss its treatments.
Read the full story here.
– CNBC